We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud
Read MoreHide Full Article
Veeva Systems Inc. (VEEV - Free Report) recently announced that its Veeva Development Cloud has been selected by Boehringer Ingelheim. The selection is expected to aid the latter in driving end-to-end processes and smooth information sharing for greater speed in the delivery of innovative therapies.
It is noteworthy to mention that Boehringer Ingelheim is a renowned research-driven biopharmaceutical company working on breakthrough therapies that aim to improve the lives of humans and animals, and creating value through innovation in areas of high unmet medical need.
The growing adoption of Veeva Systems’ applications is expected to provide a significant boost to the Veeva Development Cloud product line of its Life Sciences segment.
Significance of the Adoption
Boehringer Ingelheim’s adoption of Veeva Development Cloud product line is aimed at bringing together data and processes across clinical, regulatory and quality on a single cloud platform for the enterprise. This, in turn, will enable the company to establish a connected technology landscape for agile collaboration that can fast-track the development of novel medicines.
Adoption of Veeva Systems’ applications will also aid Boehringer Ingelheim to execute its Medicine Excellence initiative and further simplify its IT infrastructure and deliver a more consistent user experience. This is likely to make it easier to access information and collaborate cross-functionally.
Per Veeva Systems’ management, the adoption of its applications is expected to strengthen its long-standing partnership with Boehringer Ingelheim and enter the next stage of their tie-up.
Industry Prospects
Per a report by Marketsandresearch.biz, the global clinical data management system market was estimated to be $1574.8 million in 2021 and is projected to reach $4294.1 million by 2028 at a CAGR of 15.4%. Factors like a surge in clinical trials, a flourishing healthcare industry, and increasing research collaborations and partnerships are expected to drive the market.
Given the market potential, growing adoption of the company’s applications is expected to strengthen its position in the global cloud application space.
Notable Developments
This month, Veeva Systems announced solid fourth-quarter fiscal 2022 results, wherein both of its segments performed impressively. The company continued to benefit from its flagship Vault platform.
Last month, Veeva Systems announced that Idorsia Pharmaceuticals Ltd has expanded its use of Veeva Vault Clinical Suite applications. This expansion includes Veeva Vault Clinical Data Management Suite for electronic data capture and coding.
In January, Veeva Systems’ Veeva Development Cloud was selected by the Lymphoma Academic Research Organization to enhance operational efficiency across its lymphoma therapy research.
Price Performance
Shares of Veeva Systems have lost 17.6% in the past year versus the industry’s 39.2% fall. The S&P 500 rose 17.1% in the said time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 44.4% against the industry’s 52.7% fall over the past year.
IDEXX, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 18.6%.
IDEXX has gained 12.8% compared with the industry’s 5.3% growth over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 28.2% compared with the industry’s 11.2% growth over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud
Veeva Systems Inc. (VEEV - Free Report) recently announced that its Veeva Development Cloud has been selected by Boehringer Ingelheim. The selection is expected to aid the latter in driving end-to-end processes and smooth information sharing for greater speed in the delivery of innovative therapies.
It is noteworthy to mention that Boehringer Ingelheim is a renowned research-driven biopharmaceutical company working on breakthrough therapies that aim to improve the lives of humans and animals, and creating value through innovation in areas of high unmet medical need.
The growing adoption of Veeva Systems’ applications is expected to provide a significant boost to the Veeva Development Cloud product line of its Life Sciences segment.
Significance of the Adoption
Boehringer Ingelheim’s adoption of Veeva Development Cloud product line is aimed at bringing together data and processes across clinical, regulatory and quality on a single cloud platform for the enterprise. This, in turn, will enable the company to establish a connected technology landscape for agile collaboration that can fast-track the development of novel medicines.
Adoption of Veeva Systems’ applications will also aid Boehringer Ingelheim to execute its Medicine Excellence initiative and further simplify its IT infrastructure and deliver a more consistent user experience. This is likely to make it easier to access information and collaborate cross-functionally.
Per Veeva Systems’ management, the adoption of its applications is expected to strengthen its long-standing partnership with Boehringer Ingelheim and enter the next stage of their tie-up.
Industry Prospects
Per a report by Marketsandresearch.biz, the global clinical data management system market was estimated to be $1574.8 million in 2021 and is projected to reach $4294.1 million by 2028 at a CAGR of 15.4%. Factors like a surge in clinical trials, a flourishing healthcare industry, and increasing research collaborations and partnerships are expected to drive the market.
Given the market potential, growing adoption of the company’s applications is expected to strengthen its position in the global cloud application space.
Notable Developments
This month, Veeva Systems announced solid fourth-quarter fiscal 2022 results, wherein both of its segments performed impressively. The company continued to benefit from its flagship Vault platform.
Last month, Veeva Systems announced that Idorsia Pharmaceuticals Ltd has expanded its use of Veeva Vault Clinical Suite applications. This expansion includes Veeva Vault Clinical Data Management Suite for electronic data capture and coding.
In January, Veeva Systems’ Veeva Development Cloud was selected by the Lymphoma Academic Research Organization to enhance operational efficiency across its lymphoma therapy research.
Price Performance
Shares of Veeva Systems have lost 17.6% in the past year versus the industry’s 39.2% fall. The S&P 500 rose 17.1% in the said time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 44.4% against the industry’s 52.7% fall over the past year.
IDEXX, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 18.6%.
IDEXX has gained 12.8% compared with the industry’s 5.3% growth over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 28.2% compared with the industry’s 11.2% growth over the past year.